Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry.

ABSTRACT: People of African ancestry (Blacks) have increased risk of kidney failure due to numerous socioeconomic, environmental, and clinical factors. Two variants in the APOL1 gene are now thought to account for much of the racial disparity associated with hypertensive kidney failure in Blacks. However, this knowledge has not been translated into clinical care to help improve patient outcomes and address disparities. GUARDD is a randomized trial to evaluate the effects and challenges of incorporating genetic risk information into primary care. Hypertensive, non-diabetic, adults with self-reported African ancestry, without kidney dysfunction, are recruited from diverse clinical settings and randomized to undergo APOL1 genetic testing at baseline (intervention) or at one year (waitlist control). Pro

SUBMITTER: Horowitz CR 

PROVIDER: S-EPMC4818169 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature